%0 Journal Article
%T Mesenchymal Stem Cell (MSC) Transplantation in Patients with Amyotrophic Lateral Sclerosis (ALS): Is there a £¿¡é£¿£¿£¿£¿Responder Population£¿¡é£¿£¿£¿£¿? | Insight Medical Publishing
%A Aleks
%A Joanna Wojtkiewicz
%A Katarzyna Jezierska-Wozniak
%A Lukasz Grabarczyk
%A Mariusz Sowa
%A Monika Barczewska
%A Tomasz Siwek
%A W
%A Wojciech Maksymowicz
%A a Badowska
%A ra Habich
%J Journal of Neurology and Neuroscience
%D 2018
%R 10.21767/2171-6625.1000260
%X Objective: To analyze the safety and clinical effect of stem cell therapy in ALS. Methods: In phase I of the trial, ALS subjects have been intrathecally transplanted with autologous bone marrowderived mesenchymal stem cells (MSCs) using a surgical procedure. Results: We present the results of a 6-month interim analysis of the ongoing study. Intrathecal administration of MSCs into ALS patients was feasible and safe. We showed a clinical benefit evident for the entire group of patients (n=25). The mean rate of ALSFRS-R score change (decrease) pre-transplant was 1.76 ¡À 1.36 points/period whereas the mean post-transplant rate was 1.06 ¡À 0.9 points/period (p=0.014). The key finding of our study is that there appears to be a group of patients, whom we call ¡°responders¡± whose reaction to the treatment was different from the reaction of other patients we call ¡°nonresponders¡±. Conclusion: In our study the ¡°responders¡± progressed faster prior to the treatment than ¡°non-responders¡±. Hence, we hypothesize that the pre-treatment progression rate may play a role as a predictive factor and a criterion for selecting ALS patients for cell-based therapies.
%U http://www.jneuro.com/neurology-neuroscience/mesenchymal-stem-cell-msc-transplantation-in-patients-with-amyotrophic-lateral-sclerosis-als-is-there-a-responder-population.php?aid=22903